Vnitr Lek 2020, 66(4):232-235 | DOI: 10.36290/vnl.2020.066

Gastrointestinal and hepatic symptoms of tickborne diseases

Mária Budzáková1, Jan Trna1,2
1 Interní oddělení Nemocnice Boskovice
2 Gastroenterologické oddělení MOÚ Brno

While investigating patients with gastrointestinal (GI) and/or hepatic symptoms, tickborne diseases are only rarely considered to be the cause. However, the Czech Republic is an endemic region for several of tickborne diseases and, therefore, they should be a part of differential diagnosis of GI symptoms of unknown origin. This article describes GI and hepatic symptoms of several tickborne diseases - Lyme disease, ehrlichiosis, Rocky mountain spotted fever, tularemia, Colorado tick fever, tick-borne relapsing fever, Q fever and babesiosis. GI and hepatic symptoms are quite common in Lyme disease patients. The prognosis is generally favourable with antibiotics treatment, however, serious courses have been described. Lyme disease should be a part of differential diagnosis of liver tests elevation and GI symptoms in patients from endemic regions regardless erythema migrans presence. Ehrlichiosis should be a part of differential diagnosis of acute febrile illness with GI symptoms especially in the presence of leukopenia/thrombocytopenia and/or liver tests elevation. Tularemia should be considered as a rare etiology of cholestatic hepatopathy and a history of a tick bite. In general, the importance of careful patient interviewing, including the history of a tick bite, can be highlighted also as a part of investigation of patients with seemingly unrelated GI and/or hepatic symptoms.

Keywords: babesiosis, Colorado tick fever, ehrlichiosis, gastrointestinal diseases, hepatic diseases, Lyme disease, Q fever, Rocky mountain spotted fever, tick‑borne relapsing fever, tularemia, symptoms.

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Budzáková M, Trna J. Gastrointestinal and hepatic symptoms of tickborne diseases. Vnitr Lek. 2020;66(4):232-235. doi: 10.36290/vnl.2020.066.
Download citation

References

  1. Janovská D Epidemiologická situace v České republice. In: Bartůněk P (ed). Lymeská borelióza. 4. vydání. Praha: Grada Publishing 2013, 25-43.
  2. Steere AC, Bartenhagen NH, Craft JE et al. The Early Clinical Manifestations of Lyme Disease. Ann Intern Med 1983; 99: 76-82. Go to original source... Go to PubMed...
  3. Schefte DF, Nordentoft T Intestinal Pseudoobstruction Caused by Chronic Lyme Neuroborreliosis. A Case Report. J Neurogastroenterol Motil 2015; 21: 440-442. Go to original source... Go to PubMed...
  4. Kazakoff MA, Sinusas K, Macchia C Liver function test abnormalities in early Lyme disease. Arch Fam Med 1993; 2: 409-413. Go to original source... Go to PubMed...
  5. Horowitz HW, Dworkin B, Forseter G et al. Liver function in early Lyme disease. Hepatology 1996; 23: 1412-1417. Go to original source... Go to PubMed...
  6. Soloski MJ, Crowder LA, Lahey LJ et al. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One 2014; 9: e93243. Go to original source... Go to PubMed...
  7. Massaroti EM, Luger SW Rahn DW et al. Treatment of early Lyme disease. Am J Med 1992; 92: 396-403. Go to original source... Go to PubMed...
  8. Zanchi AC, Gingold AR, Theise ND et al. Necrotizing granulomatous hepatitis as an unusual manifestation of Lyme disease. Dig Dis Sci 2007; 52: 2629-2632. Go to original source... Go to PubMed...
  9. Stanek G, Strle F Lyme borreliosis‑from tick bite to diagnosis and treatment. FEMS Microbiol Rev 2018; 42: 233-258. Go to original source... Go to PubMed...
  10. Derdáková M, Lencáková D Association of genetic variability within the Borrelia burgdorferi sensu lato with the ecology, epidemiology of Lyme borreliosis in Europe. Ann Agric Environ Med 2005; 12: 165-172.
  11. Wang G, van Dam AP, Schwartz I et al. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications. Clin Microbiol Rev 1999; 12: 633-653. Go to original source... Go to PubMed...
  12. Stanek G, Reiter M The expanding Lyme Borrelia complex - clinical significance of genomic species? Clin Microbiol Infect 2011; 17: 487-493. Go to original source... Go to PubMed...
  13. Swanson SJ, Neitzel D, Reed KD et al. Coinfections acquired from ixodes ticks. Clin Microbiol Rev 2006; 19: 708-727. Go to original source... Go to PubMed...
  14. Moutailler S, Valiente Moro C, Vaumourin E et al. Co‑infection of Ticks: The Rule Rather Than the Exception. PLoS Negl Trop Dis 2016; 10: e0004539. Go to original source... Go to PubMed...
  15. Stuen S, Granquist EG, Silaghi C Anaplasma phagocytophilum - a widespread multi‑host pathogen with highly adaptive strategies. Front Cell Infect Microbiol. 2013; 3: 31. Go to original source... Go to PubMed...
  16. Comstock LE, Thomas DD Penetration of endothelial cell monolayers by Borrelia burgdorferi. Infect Immun 1989; 57: 1626-1628. Go to original source... Go to PubMed...
  17. Duray PH, Steere AC Clinical pathologic correlations of Lyme disease by stage. Ann NY Acad Sci 1988; 539: 65-79. Go to original source... Go to PubMed...
  18. Aberer E, Brunner C, Suchanek G et al. Molecular mimicry and Lyme borreliosis: a shared antigenic determinant between Borrelia burgdorferi and human tissue. Ann Neurol 1989; 26: 732-737. Go to original source... Go to PubMed...
  19. Middelveen MJ, McClain SA, Bandoski C et al. Granulomatous hepatitis associated with chronic Borrelia burgdorferi infection: a case report. Research 2014; 1: 875. Go to original source...
  20. Zaidi SA, Singer C Gastrointestinal and hepatic manifestations of tickborne diseases in the United States. Clin Infect Dis 2002; 34: 1206-1212. Go to original source... Go to PubMed...
  21. Olano JP, Hogrefe W, Seaton B et al. Clinical manifestations, epidemiology, and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting. Clin Diagn Lab Immunol 2003; 10: 891-896. Go to original source... Go to PubMed...
  22. Nutt AK, Raufman J Gastrointestinal and hepatic manifestations of human ehrlichiosis: 8 cases and a review of the literature. Dig Dis 1999; 17: 37-43. Go to original source... Go to PubMed...
  23. Gershel JC Human granulocytic ehrlichiosis presenting as abdominal pain. Pediatrics 2000; 106: 602-604. Go to PubMed...
  24. Wallace BJ, Brady G, Ackman DM et al. Human Granulocytic Ehrlichiosis in New York. Arch Intern Med 1998; 158: 769-773. Go to original source... Go to PubMed...
  25. Schiffman J, Haq M, Procopio F et al. Ehrlichiosis infection in a 5-year‑old boy with neutropenia, anemia, thrombocytopenia, and hepatosplenomegaly. J Pediatr Hematol Oncol 2001; 23: 324-327. Go to original source... Go to PubMed...
  26. Ismail N, McBride JW Tick‑Borne Emerging Infections: Ehrlichiosis and Anaplasmosis. Clin Lab Med 2017; 37: 317-340. Go to original source... Go to PubMed...
  27. Parola P, Paddock CD, Socolovschi C et al. Update on Tick‑Borne Rickettsioses around the World: a Geographic Approach. Clin Microbiol Rev 2013; 26: 657-702. Go to original source... Go to PubMed...
  28. Dahlgren FS, Holman RC, Paddock CD et al. Fatal Rocky Mountain Spotted Fever in the United States, 1999-2007. Am J Trop Med Hyg 2012; 86: 713-719. Go to original source... Go to PubMed...
  29. Walker DH, Henderson FW, Hutchins GM Rocky Mountain spotted fever: mimicry of appendicitis or acute surgical abdomen? Am J Dis Child 1986; 140: 742-744. Go to original source... Go to PubMed...
  30. Middleton DB Rocky Mountain spotted fever: gastrointestinal and laboratory manifestations. South Med J 1978; 71: 629-632. Go to original source... Go to PubMed...
  31. Regan JJ, Traeger MS, Humpherys D et al. Risk factors for fatal outcome from rocky mountain spotted fever in a highly endemic area‑Arizona, 2002-2011. Clin Infect Dis 2015; 60: 1659-1666. Go to original source... Go to PubMed...
  32. Gottlieb M, Long B, Koyfman A The Evaluation and Management of Rocky Mountain Spotted Fever in the Emergency Department: a Review of the Literature. J Emerg Med 2018; 55: 42-50. Go to original source... Go to PubMed...
  33. Randall MB, Walker DH Rocky Mountain spotted fever: gastrointestinal and pancreatic lesions and rickettsial infection. Arch Pathol Lab Med 1984; 108: 963-967.
  34. Sahni A, Fang R, Sahni SK et al. Pathogenesis of Rickettsial Diseases: Pathogenic and Immune Mechanisms of an Endotheliotropic Infection. Annu Rev Pathol 2019; 14: 127-152. Go to original source... Go to PubMed...
  35. Kirkland KB, Wilkinson WE, Sexton DJ Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis 1995; 20: 1118-1121. Go to original source... Go to PubMed...
  36. Zellner B, Huntley JF Ticks and Tularemia: Do We Know What We Don't Know? Front Cell Infect Microbiol 2019; 9: 146. Go to original source... Go to PubMed...
  37. Dienst FT Tularemia: a perusal of three hundred thirty‑nine cases. J La State Med Soc 1963; 115: 114-1127.Další literatura u autorů a na www.casopisvnitrnilekarstvi.cz Go to PubMed...
  38. Ortego TJ, Hutchins LF, Rice J et al. Tularemic hepatitis presenting as obstructive jaundice. Gastroenterology 1986; 91: 461-463. Go to original source... Go to PubMed...
  39. Gourdeau M, Lamothe F, Ishak M et al. Hepatic abscess complicating ulceroglandular tularemia. Can Med Assoc J 1983; 129: 1286-1288. Go to PubMed...
  40. Yendell SJ, Fischer M, Staples JE Colorado tick fever in the United States, 2002-2012. Vector Borne Zoonotic Dis 2015; 15: 311-316. Go to original source... Go to PubMed...
  41. Goodpasture HC, Poland JD, Francy DB et al. Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973-1974. Ann Intern Med 1978; 88: 303-310. Go to original source... Go to PubMed...
  42. Loge RV Acute hepatitis associated with Colorado tick fever. West J Med 1985; 142: 91-92.
  43. Dworkin MS, Schwan TG, Anderson jr. DE Tick‑borne relapsing fever in North America. Med Clin North Am 2002; 86: 417-433. Go to original source... Go to PubMed...
  44. Mafi N, Yaglom HD, Levy C et al. Tick‑Borne Relapsing Fever in the White Mountains, Arizona, USA, 2013-2018. Emerg Infect Dis 2019; 25: 649-653. Go to original source... Go to PubMed...
  45. Dworkin MS, Schwan TG, Anderson jr. DE et al. Tick‑borne relapsing fever. Infect Dis Clin North Am 2008; 22: 449-468. Go to original source... Go to PubMed...
  46. Rath PM, Rögler G, Schönberg A et al. Relapsing fever and its serological discrimination from Lyme borreliosis. Infection 1992; 20: 283-286. Go to original source... Go to PubMed...
  47. Reisfeld S, Hasadia Mhamed S, Stein M et al. Epidemiological, clinical and laboratory characteristics of acute Q fever in an endemic area in Israel, 2006-2016. Epidemiol Infect 2019; 147: e131. Go to original source... Go to PubMed...
  48. Lee M, Jang JJ, Kim YS et al. Clinicopathologic features of Q fever patients with acute hepatitis. Korean J Pathol 2012; 46: 10-14. Go to original source...
  49. Aguilar‑Olivos N, del Carmen Manzano‑Robleda M, Gutiérrez‑Grobe Y et al. Granulomatous hepatitis caused by Q fever: a differential diagnosis of fever of unknown origin. Ann Hepatol 2013; 12: 138-141. Go to original source... Go to PubMed...
  50. Vannier EG, Diuk‑Wasser MA, Ben Mamoun C et al. Babesiosis. Infect Dis Clin North Am 2015; 29: 357-370. Go to original source... Go to PubMed...
  51. Pruthi RK, Marshall WF, Wiltsie JC et al. Human babesiosis. Mayo Clin Proc 1995; 70: 853-862. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.